ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : P-type ATPase
Scheme : Project Grants
Clear All
Filter by Field of Research
Endocrinology (7)
Autoimmunity (4)
Cellular Immunology (3)
Central Nervous System (3)
Medical and Health Sciences not elsewhere classified (3)
Cell Metabolism (2)
Medical Virology (2)
Public Health and Health Services not elsewhere classified (2)
Signal Transduction (2)
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) (1)
Biomolecular Modelling and Design (1)
Cardiology (incl. Cardiovascular Diseases) (1)
Cell Development, Proliferation and Death (1)
Cell Physiology (1)
Clinical Sciences not elsewhere classified (1)
Clinical and Sports Nutrition (1)
Complementary and Alternative Medicine not elsewhere classified (1)
Innate Immunity (1)
Medical Molecular Engineering of Nucleic Acids and Proteins (1)
Medical Physiology not elsewhere classified (1)
Mental Health (1)
Nutritional Physiology (1)
Pharmaceutical Sciences (1)
Receptors and Membrane Biology (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (43)
Filter by Status
Closed (43)
Filter by Scheme
Project Grants (43)
Filter by Country
Australia (9)
Colombia (1)
Filter by Australian State/Territory
VIC (7)
SA (2)
QLD (1)
  • Researchers (0)
  • Funded Activities (43)
  • Organisations (0)
  • Funded Activity

    To Biochemically Trick P-Glycoprotein (Pgp) To Target Resistance Via Lysosomal Pgp

    Funder
    National Health and Medical Research Council
    Funding Amount
    $603,848.00
    Summary
    We have discovered an innovative biochemical strategy whereby our novel compounds exploit and trick a part of the detoxification machinery, that is the transporter, P-glycoprotein, to specifically kill drug resistant cancer cells. Herein, we take advantage of this biochemical mechanism to design novel and safe drugs to selectively target resistant tumours.
    More information
    Funded Activity

    Oxidative Regulation Of The Na Pump- A New Player In Vascular Function In Health And Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $504,427.00
    Summary
    Oxidative stress is a major player in hypertension, atherosclerosis, diabetes and ageing, but we have struggled to develop a therapy to successfully combat in heart and vascular cells in large clinical trials. We have discovered a new role for membrane protein FXYD1, to protect key heart and vascular proteins from functional impairment secondary to oxidative stress. We will investigate its role in protecting against vascular disease, and test novel therapies based on this endogenous protector.
    More information
    Funded Activity

    Microparticles And Selective Trait Dominance In Multidrug Resistant Cancers

    Funder
    National Health and Medical Research Council
    Funding Amount
    $478,115.00
    Summary
    Multidrug resistance (MDR) is the cause of treatment failure in 90% of patients with metastatic cancer. We recently discovered a novel resistance mechanism in which microparticles provide a vehicle for intercellular transfer of MDR. We now report that MP play an even more significant role in conferring MDR, by the ñre-templatingî of cancer cell traits. This has considerable potential for translation into clinical outcomes with the identification of alternative drug targets and therapeutics for t .... Multidrug resistance (MDR) is the cause of treatment failure in 90% of patients with metastatic cancer. We recently discovered a novel resistance mechanism in which microparticles provide a vehicle for intercellular transfer of MDR. We now report that MP play an even more significant role in conferring MDR, by the ñre-templatingî of cancer cell traits. This has considerable potential for translation into clinical outcomes with the identification of alternative drug targets and therapeutics for the circumvention of MDR clinically.
    Read more Read less
    More information
    Funded Activity

    A Mechanistic Approach To Therapy Development For Chronic Traumatic Encephalopathy Using Small And Large Animal Models Of Concussion

    Funder
    National Health and Medical Research Council
    Funding Amount
    $492,844.00
    Summary
    Repeated concussion in athletes has recently been associated with the development of a neurodegenerative disorder known as chronic traumatic encephalopathy (CTE). While the neuropathology seems to be well characterised, the mechanisms associated with CTE development are not. This proposal will demonstrate that mechanically induced release of the neurotransmitter substance P accounts for much of the neuropathology in CTE, and will develop a novel therapy that will prevent such development.
    More information
    Funded Activity

    Understanding Multidrug Resistance In Cancer: Identification Of The Substrate And Inhibitor Binding Sites In P-glycoprotein

    Funder
    National Health and Medical Research Council
    Funding Amount
    $284,343.00
    Summary
    Cancers expressing the multidrug transporter P-glycoprotein (P-gp) are resistant to chemotherapy. The clinical impact of P-gp is so large that the National Cancer Institute (USA) “profiles” all anticancer drugs for transport by P-gp, primarily because the mechanism of drug binding and transport by P-gp is unknown. The aim of this proposal is to understand the molecular details of how drugs bind to and interact with P-gp, a major step in our understanding of P-gp mediated chemotherapy resistance.
    More information
    Funded Activity

    The Role Of Apoptotic Caspases In Regulating Type I Interferon Production

    Funder
    National Health and Medical Research Council
    Funding Amount
    $791,746.00
    Summary
    Type I interferons (IFNs) are potent anti-viral cytokines. Dysregulated type I IFN responses result in major pathologies, e.g., embryonic lethality and defects in tissue homeostasis. We have identified a novel molecular mechanism regulating IFN production that relies on the host’s own apoptotic caspases. We hypothesize that apoptotic caspases critically regulate IFN responses during the process of cell death, with implications for tissue homeostasis and host responses to infection.
    More information
    Funded Activity

    Controlling Neuroinflammation In Alzheimers Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $639,577.00
    Summary
    Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.
    More information
    Funded Activity

    Type I Interferon Signalling In Bacterial Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $738,274.00
    Summary
    Infectious diseases are a leading cause of death in Australia. Activation of disease-fighting inflammasomes sets in motion rapid immune defenses against pathogens. In this project, we explore how cell-cell communication molecules known as type I interferons communicate with inflammasomes to achieve the best outcome in the body in response to deadly bacterial infection. Understanding how these signals communicate with one another could reveal new ways to fight infectious diseases.
    More information
    Funded Activity

    Intervention To Reduce The Risk Of Diabetic Retinopathy And Early Adverse Retinal Changes In Type 1 Diabetes

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,294,846.00
    Summary
    The long term effects of young onset T1D may be devastating: diabetes is the leading cause of visual loss in young adults in Australia and other countries. We have the unique opportunity to investigate whether ACEI and statins will modify retinopathy through our collaboration with an already funded international multicentre trial. This study will treat adolescents for 4 years and will follow them for the next 5-10 years. We will use novel measures of retinal blood vessels size and fractals.
    More information
    Funded Activity

    Understanding Neuroinflammation In Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,043,216.00
    Summary
    This project opens a new line of enquiry into the cellular signalling mechanisms involved in the progression of AD and establishes whether targeting the involvement of type-1 IFN signalling influences the evolution of AD. New and novel approaches are clearly required to treat AD. Importantly, we believe that neuroinflammation is common to all causes of dementia and targeting the neuroinflammatory pathways has much wider implications than targeting the primary causative pathway.
    More information

    Showing 1-10 of 43 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback